{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:43Z","timestamp":1793228143833,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Monitoring of pathogen resistance profiles is necessary to guide empirical antibiotic therapy before culture and sensitivity results become available. The aim of this study was to describe current antibiotic resistance patterns of five most frequent causative uropathogens in a Department of Urology of a tertiary referral centre in Central Europe over a period of nine years. The Hospital Department of Clinical Microbiology database was used to extract data on all positive urine samples from inpatients in the Department of Urology between 2011 and 2019. Numbers of susceptible and resistant isolates per year were calculated for five most frequent uropathogens: Escherichia coli, Enterococcus spp., Klebsiella spp., Pseudomonas aeruginosa, and Proteus spp. Antimicrobial agents selected for the survey included: ampicillin, amoxicillin\/clavulanic acid, piperacillin\/tazobactam; cefuroxime, cefotaxime, ceftazidime and cefepime; ciprofloxacin and ofloxacin; gentamicin and amikacin; ertapenem, meropenem and imipenem; trimethoprim-sulfamethoxazole (co-trimoxazole), nitrofurantoin, colistin, and vancomycin. High resistance rates of Gram-negative uropathogens were demonstrated to most common antimicrobials, with statistically significant increasing or decreasing trends in some cases. No carbapenem-resistant Enterobacteriaceae were isolated. Vancomycin-resistant Enterococcus spp. strains were rare in our population.<\/jats:p>","DOI":"10.3390\/antibiotics9090630","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T09:40:56Z","timestamp":1600767656000},"page":"630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Current Antibiotic Resistance Trends of Uropathogens in Central Europe: Survey from a Tertiary Hospital Urology Department 2011\u20132019"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-8698","authenticated-orcid":false,"given":"Jan","family":"Hrbacek","sequence":"first","affiliation":[{"name":"Department of Urology, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Cermak","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Zachoval","sequence":"additional","affiliation":[{"name":"Department of Urology, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, 140 59 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Manyi-Loh, C., Mamphweli, S., Meyer, E., and Okoh, A. (2018). Antibiotic use in agriculture and its consequential resistance in environmental sources: Potential public health implications. Molecules, 23.","DOI":"10.3390\/molecules23040795"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00345-013-1031-5","article-title":"Increasing prevalence of ciprofloxacin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates","volume":"31","author":"Bonkat","year":"2013","journal-title":"World J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1800159","DOI":"10.2807\/1560-7917.ES.2019.24.5.1800159","article-title":"Bloodstream infections due to carbapenemas eproducing Enterobacteriaceae in Italy: Results from nationwide surveillance, 2014 to 2017","volume":"24","author":"Iacchini","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1464-410X.2011.10528.x","article-title":"The changing pattern of antimicrobial resistance within 42 033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999\u20132009","volume":"109","author":"Cullen","year":"2011","journal-title":"BJUI Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12866-016-0749-9","article-title":"Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe","volume":"16","author":"Malespine","year":"2016","journal-title":"BMC Microbiol."},{"key":"ref_7","first-page":"176","article-title":"Antibiotic resistance: Microbiological profile of urinary tract infections in Mexico","volume":"87","year":"2019","journal-title":"Cir. Cir."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1473-3099(05)70189-4","article-title":"AMR Resistance in developing countries","volume":"5","author":"Okeke","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fasugba, O., Mitchell, B.G., Mnatzaganian, G., Das, A., Collignon, P., and Gardner, A. (2016). Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164306"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3904\/kjim.2015.257","article-title":"Changing trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae bacteremia","volume":"33","author":"Hyun","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1099\/jmm.0.000421","article-title":"Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013\u20132015","volume":"66","author":"Karlowsky","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_12","unstructured":"World Health Organization (2019). 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, WHO. Available online: https:\/\/www.who.int\/medicines\/areas\/rational_use\/antibacterial_agents_clinical_development\/en\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"taz036","DOI":"10.1093\/jtm\/taz036","article-title":"Global geographic trends in antimicrobial resistance: The role of international travel","volume":"26","author":"Frost","year":"2019","journal-title":"J. Travel Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_15","unstructured":"Wein, A., and Kavoussi, L. (2012). Infections of the urinary tract. Campbell-Walsh Urology, Elsevier Saunders. [10th ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fran\u00e7ois, M., Hanslik, T., Dervaux, B., Le Strat, Y., Souty, C., Vaux, S., Maugat, S., Rondet, C., Sarazin, M., and Heym, B. (2016). The economic burden of urinary tract infections in women visiting general practices in France: A cross-sectional survey. BMC Health Serv. Res., 16.","DOI":"10.1186\/s12913-016-1620-2"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e020251","DOI":"10.1136\/bmjopen-2017-020251","article-title":"Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study","volume":"8","author":"Pujol","year":"2018","journal-title":"BMJ Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11845-016-1538-z","article-title":"Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005\u20132014","volume":"186","author":"Stapleton","year":"2017","journal-title":"Ir. J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.euf.2016.09.006","article-title":"Trends in Antibiotic Resistance in Urologic Practice","volume":"2","author":"Kandil","year":"2016","journal-title":"Eur. Urol. Focus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/dkr190","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe (1997\u20132009)","volume":"66","author":"Adriaenssens","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofy198","DOI":"10.1093\/ofid\/ofy198","article-title":"An assessment of inappropriate antibiotic use and guideline adherence for uncomplicated urinary tract infections","volume":"5","author":"Durkin","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_23","first-page":"1865","article-title":"Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010\u20132011","volume":"315","author":"Hersh","year":"2016","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5811\/westjem.2020.1.45944","article-title":"Appropriateness of Antibiotic Prescriptions for Urinary Tract Infections","volume":"21","author":"Chardavoyne","year":"2020","journal-title":"West. J. Emerg. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105966","DOI":"10.1016\/j.ijantimicag.2020.105966","article-title":"Office-based approach to urinary tract infections in 50,000 patients: Results from the REWIND study","volume":"56","author":"Cai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/phar.1868","article-title":"Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications","volume":"37","author":"Luepke","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","article-title":"Critical analysis of antibacterial agents in clinical development","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","article-title":"Non-traditional antibacterial therapeutic options and challenges","volume":"26","author":"Theuretzbacher","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3389\/fmicb.2018.01218","article-title":"Mechanism of anti-bacterial activity of zinc oxide nanoparticle against Carbapenem-Resistant Acinetobacter baumannii","volume":"9","author":"Tiwari","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jsps.2018.03.004","article-title":"Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli","volume":"26","author":"Abdelhamid","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Iseppi, R., Di Cerbo, A., Aloisi, P., Manelli, M., Pellesi, V., Provenzano, C., Camellini, S., Messi, P., and Sabia, C. (2020). In vitro activity of essential oils against planktonic and biofilm cells of extended-spectrum \u03b2-lactamase (ESBL)\/carbapenamase-producing gram-negative bacteria involved in human nosocomial infections. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050272"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fmicb.2016.00465","article-title":"Bacteriophages as Potential Treatment for Urinary Tract Infections","volume":"7","author":"Sybesma","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1099\/jmm.0.000498","article-title":"Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary","volume":"66","author":"Magyar","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00345-015-1718-x","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: Incidence and antibiotic susceptibility profile over 9 years","volume":"34","author":"Toner","year":"2016","journal-title":"World J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.11604\/pamj.2017.28.29.11402","article-title":"Profil \u00e9pid\u00e9miologique des ent\u00e9robact\u00e9ries uropathog\u00e8nes productrices de b\u00eata-lactamases \u00e0 spectre \u00e9largi","volume":"28","author":"Sbiti","year":"2017","journal-title":"Pan Afr. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11255-015-1018-9","article-title":"Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: Focus on susceptibility to fosfomycin","volume":"47","author":"Cho","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fajfr, M., Louda, M., Paterov\u00e1, P., Ryskova, L., Pacovsk\u00fd, J., Ko\u0161ina, J., \u017demli\u010dkov\u00e1, H., and Brodak, M. (2017). The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: Data from a unicentric study. BMC Urol., 17.","DOI":"10.1186\/s12894-017-0222-6"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jac\/dkq538","article-title":"A 12 year (1998\u20132009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals","volume":"66","author":"Beisser","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., and Urb\u00e1n, E. (2019). Comparative Epidemiology and Resistance Trends of Proteae in Urinary Tract Infections of Inpatients and Outpatients: A 10-Year Retrospective Study. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030091"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lupo, A., Haenni, M., and Madec, J.-Y. (2018). Antimicrobial Resistance in Acinetobacter spp. and Pseudomonas spp.. Microbiol. Spectr., 6.","DOI":"10.1128\/microbiolspec.ARBA-0007-2017"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1128\/JB.182.22.6482-6489.2000","article-title":"Development and Dynamics of Pseudomonas sp. Biofilms","volume":"182","author":"Brinch","year":"2000","journal-title":"J. Bacteriol."},{"key":"ref_42","unstructured":"EMEA (2020, April 12). Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/news\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eururo.2018.10.057","article-title":"In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default ?","volume":"75","author":"Bonkat","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4111\/icu.2016.57.2.129","article-title":"Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom","volume":"57","author":"Toner","year":"2016","journal-title":"Investig. Clin. Urol."},{"key":"ref_45","unstructured":"Bonkat, G., Bartoletti, R., Bruy\u00e8re, F., Cai, T., Geerlings, S., K\u00f6ves, B., Schubert, S., and Wagenlehner, F. (2020, September 17). Urological Infections. Available online: https:\/\/uroweb.org\/guideline\/urological-infections\/."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wagenlehner, F.M., Tando\u011fdu, Z., Bartoletti, R., Cai, T., Cek, M., Kulchavenya, E.V., Koves, B., Naber, K., Perepanova, T.S., and Tenke, P. (2016). The global prevalence of infections in urology study: A long-term, worldwide surveillance study on urological infections. Pathogens, 5.","DOI":"10.3390\/pathogens5010010"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:15Z","timestamp":1760177535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["antibiotics9090630"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9090630","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]}}}